FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313245877> ?p ?o ?g. }

• W4313245877 endingPage "112" @default.
• W4313245877 startingPage "112" @default.
• W4313245877 abstract "Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in adults with previously treated EGFR ex20ins+ metastatic non-small cell lung cancer (mNSCLC) in the EXCLAIM extension cohort of a phase 1/2 study (N = 96; NCT02716116). We assessed patient-reported outcomes (PROs) with mobocertinib 160 mg once daily (28-day cycles) in EXCLAIM (N = 90) with the European Organisation for Research and Treatment of Cancer Core Quality-of-Life Questionnaire (EORTC QLQ-C30) v3.0, lung cancer module (QLQ-LC13), EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire, and selected PRO Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) questionnaire. Median treatment duration was 6.8 (range, 0.0-18.8) months (median follow-up: 13.0 [0.7-18.8] months; data cutoff: 1 November 2020). Clinically meaningful improvements in lung cancer symptoms measured by EORTC QLQ-LC13 were observed for dyspnea (54.4% of patients), cough (46.7%), and chest pain (38.9%), evident at cycle 2 and throughout treatment (least-squares mean [LSM] changes from baseline: dyspnea, -3.2 [p = 0.019]; cough, -9.3 [p < 0.001]; chest pain, -8.2 [p < 0.001]). EORTC QLQ-C30 results indicated no statistically significant changes in global health status/quality of life (LSM change from baseline: -1.8 [p = 0.235]). On symptom scores, significant worsening from baseline was observed for diarrhea (LSM change from baseline: +34.1; p < 0.001) and appetite loss (+6.6; p = 0.004), while improvements were observed for dyspnea (LSM change from baseline: -5.1 [p = 0.002]), insomnia (-6.5 [p = 0.001]), and constipation (-5.7 [p < 0.001]). EQ-5D-5L health status was maintained. Common PRO-CTCAE symptoms were diarrhea, dry skin, rash, and decreased appetite (mostly low grade); in the first 24 weeks of treatment, 64.4% of patients had worsening diarrhea frequency and 67.8% had worsening dry skin severity. Overall, PROs with mobocertinib showed clinically meaningful improvement in lung cancer-related symptoms, with health-related quality of life maintained despite changes in some adverse event symptom scales." @default.
• W4313245877 created "2023-01-06" @default.
• W4313245877 creator A5012240386 @default.
• W4313245877 creator A5013551992 @default.
• W4313245877 creator A5024628268 @default.
• W4313245877 creator A5048231332 @default.
• W4313245877 creator A5048675362 @default.
• W4313245877 creator A5054676638 @default.
• W4313245877 creator A5056924605 @default.
• W4313245877 creator A5058521062 @default.
• W4313245877 creator A5060033755 @default.
• W4313245877 creator A5079966483 @default.
• W4313245877 creator A5088178599 @default.
• W4313245877 creator A5090068456 @default.
• W4313245877 date "2022-12-23" @default.
• W4313245877 modified "2023-10-17" @default.
• W4313245877 title "Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort" @default.
• W4313245877 cites W1990166011 @default.
• W4313245877 cites W2003972894 @default.
• W4313245877 cites W2109567704 @default.
• W4313245877 cites W2167571044 @default.
• W4313245877 cites W2838798742 @default.
• W4313245877 cites W2884105696 @default.
• W4313245877 cites W2896011288 @default.
• W4313245877 cites W2947027930 @default.
• W4313245877 cites W2953226611 @default.
• W4313245877 cites W2976516489 @default.
• W4313245877 cites W2981389891 @default.
• W4313245877 cites W3129535020 @default.
• W4313245877 cites W3132930574 @default.
• W4313245877 cites W3206796634 @default.
• W4313245877 cites W4293733558 @default.
• W4313245877 doi "https://doi.org/10.3390/jcm12010112" @default.
• W4313245877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36614913" @default.
• W4313245877 hasPublicationYear "2022" @default.
• W4313245877 type Work @default.
• W4313245877 citedByCount "4" @default.
• W4313245877 countsByYear W43132458772022 @default.
• W4313245877 countsByYear W43132458772023 @default.
• W4313245877 crossrefType "journal-article" @default.
• W4313245877 hasAuthorship W4313245877A5012240386 @default.
• W4313245877 hasAuthorship W4313245877A5013551992 @default.
• W4313245877 hasAuthorship W4313245877A5024628268 @default.
• W4313245877 hasAuthorship W4313245877A5048231332 @default.
• W4313245877 hasAuthorship W4313245877A5048675362 @default.
• W4313245877 hasAuthorship W4313245877A5054676638 @default.
• W4313245877 hasAuthorship W4313245877A5056924605 @default.
• W4313245877 hasAuthorship W4313245877A5058521062 @default.
• W4313245877 hasAuthorship W4313245877A5060033755 @default.
• W4313245877 hasAuthorship W4313245877A5079966483 @default.
• W4313245877 hasAuthorship W4313245877A5088178599 @default.
• W4313245877 hasAuthorship W4313245877A5090068456 @default.
• W4313245877 hasBestOaLocation W43132458771 @default.
• W4313245877 hasConcept C121608353 @default.
• W4313245877 hasConcept C126322002 @default.
• W4313245877 hasConcept C143998085 @default.
• W4313245877 hasConcept C159110408 @default.
• W4313245877 hasConcept C197934379 @default.
• W4313245877 hasConcept C2776256026 @default.
• W4313245877 hasConcept C2777793932 @default.
• W4313245877 hasConcept C2779951463 @default.
• W4313245877 hasConcept C71924100 @default.
• W4313245877 hasConcept C72563966 @default.
• W4313245877 hasConcept C90924648 @default.
• W4313245877 hasConceptScore W4313245877C121608353 @default.
• W4313245877 hasConceptScore W4313245877C126322002 @default.
• W4313245877 hasConceptScore W4313245877C143998085 @default.
• W4313245877 hasConceptScore W4313245877C159110408 @default.
• W4313245877 hasConceptScore W4313245877C197934379 @default.
• W4313245877 hasConceptScore W4313245877C2776256026 @default.
• W4313245877 hasConceptScore W4313245877C2777793932 @default.
• W4313245877 hasConceptScore W4313245877C2779951463 @default.
• W4313245877 hasConceptScore W4313245877C71924100 @default.
• W4313245877 hasConceptScore W4313245877C72563966 @default.
• W4313245877 hasConceptScore W4313245877C90924648 @default.
• W4313245877 hasIssue "1" @default.
• W4313245877 hasLocation W43132458771 @default.
• W4313245877 hasLocation W43132458772 @default.
• W4313245877 hasLocation W43132458773 @default.
• W4313245877 hasOpenAccess W4313245877 @default.
• W4313245877 hasPrimaryLocation W43132458771 @default.
• W4313245877 hasRelatedWork W1967103478 @default.
• W4313245877 hasRelatedWork W2032912323 @default.
• W4313245877 hasRelatedWork W2111314921 @default.
• W4313245877 hasRelatedWork W2372561159 @default.
• W4313245877 hasRelatedWork W2390152934 @default.
• W4313245877 hasRelatedWork W2603773853 @default.
• W4313245877 hasRelatedWork W2809998966 @default.
• W4313245877 hasRelatedWork W3031099491 @default.
• W4313245877 hasRelatedWork W3043620221 @default.
• W4313245877 hasRelatedWork W3043650857 @default.
• W4313245877 hasVolume "12" @default.
• W4313245877 isParatext "false" @default.
• W4313245877 isRetracted "false" @default.
• W4313245877 workType "article" @default.